WW International targets $700M revenue by 2025 with digital transformation amid rising GLP-1 demand

Strategic Shifts and Growth Initiatives

WW International, Inc. (WW) has taken significant steps to redefine its approach in the weight management sector during the third quarter of 2025. The company's leadership, including President and CEO Tara Comonte, emphasized a renewed focus on growth and innovation. Comonte highlighted that the company is embracing the GLP-1 medication trend as a pivotal element of its strategy, stating, "The future of weight management will be built on an integrated approach that pairs clinical care and medication access with structured nutrition, movement and accountability."

This strategic pivot is reflected in the ongoing digital transformation of the WeightWatchers app and website. The CEO explained that the app is being completely replatformed to eliminate legacy barriers between clinical and behavioral offerings, allowing members to seamlessly transition across programs. The first version of the new app is expected to launch by early next year, aligning with peak season demand, with continuous improvements planned through 2026.

Leadership and Expansion

New appointments have been made to drive this digital and community-focused strategy. Helene Causse has joined as Chief Technology Officer, while Julie Rice has been appointed as Chief Experience Officer. These roles are critical in advancing WW’s digital initiatives and enhancing member experiences.

In addition to internal changes, the company has expanded its services to include menopause support and formed strategic partnerships with pharmaceutical companies such as Novo Nordisk and Amazon Pharmacy. These collaborations aim to provide more comprehensive care options for members.

Financial Performance and Outlook

Financial results for Q3 showed a revenue decline of 11% year-over-year, reaching $172 million. However, there were notable increases in clinical revenue, which rose 35%, and a significant jump in clinical subscribers, up 60% to 124,000. Behavioral revenue, on the other hand, declined by 16%, with end-of-period behavioral subscribers dropping to 2.9 million, a 20% decrease from the previous year.

Despite these challenges, the company reported strong adjusted EBITDA margins of nearly 25%. CFO Felicia DellaFortuna expressed confidence in the financial outlook, narrowing full-year fiscal 2025 guidance to the higher end of previously provided ranges, expecting revenue between $695 million and $700 million, with adjusted EBITDA projected at $145 million to $150 million.

Challenges and Mitigation Strategies

While the company is optimistic about its future, it acknowledges ongoing challenges, including persistent behavioral pressures and competition from compounded medication providers. DellaFortuna noted that the compounded medication landscape remains complex, with competitors offering products at significantly lower prices.

To address these issues, WW is focusing on digital transformation, expanding clinical offerings, and forming strategic partnerships. The company is also investing in technology and marketing to offset headwinds and maintain its competitive edge.

Analyst Perspectives and Market Sentiment

Analysts have expressed a positive sentiment towards WW’s recent developments, particularly highlighting the app overhaul, strategic partnerships, and progress in retention. Management maintained a confident tone in prepared remarks but displayed a more nuanced, cautiously optimistic outlook during Q&A discussions.

Compared to previous quarters, there is a clear shift from defensive explanations of reorganization and headwinds to a focus on execution, innovation, and expanded leadership roles. This change reflects the company's growing confidence in its long-term strategy and ability to navigate market challenges.

Future Outlook and Strategic Focus

Looking ahead, WW is positioning itself to capitalize on the surging demand for GLP-1 medications and the evolving weight management landscape. The company is investing in technology, product, and brand modernization to drive long-term growth and enhance shareholder value.

With a narrowed revenue guidance and a focus on digital integration, clinical subscriber growth, and strategic partnerships, WW is well-positioned to navigate the complexities of the market and emerge stronger in the coming years.